Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/25/2025 | $15.00 | Outperform | Wedbush |
| 11/20/2023 | $10.00 | Overweight | JP Morgan |
| 9/18/2023 | $9.00 → $10.00 | Sector Perform → Outperform | RBC Capital Mkts |
| 8/4/2023 | $11.00 | Hold → Buy | Jefferies |
| 7/13/2023 | $10.00 | Neutral → Buy | BofA Securities |
| 2/22/2023 | $14.00 | Hold → Buy | Needham |
| 11/2/2022 | $14.00 → $16.00 | In-line → Outperform | Evercore ISI |
| 8/5/2022 | Outperform → Perform | Oppenheimer |
4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)
4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)
4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)
RESEARCH TRIANGLE PARK, N.C., Sept. 05, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Donald S. Fong, MD, MPH, has been appointed as the company's new chief medical officer, effective immediately. Dr. Fong joins Dr. Helen Thackray, the company's chief research and development officer, and Dr. Bill Sheridan, the company's chief development officer, as physicians on the company's leadership team. "We continue to advance our pipeline of novel therapies to treat diseases with significant unmet needs, including programs in Netherton syndrome and diabetic macular edema that we expect will enter the clinic this year and next year, respectively. Dona
RESEARCH TRIANGLE PARK, N.C., March 31, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced the appointment of Dr. Nancy Hutson as chair of its board of directors, effective immediately. "I am honored to succeed Bob Ingram. He was a model of effective board leadership for us. Our board is comprised of exceptional people with diverse experience and I am excited to continue working alongside them and the management team to deliver innovative new therapies to patients with rare diseases," said Dr. Hutson. Dr. Hutson was appointed to the board in January 2012, bringing over 30 years of experience as a seasoned professional and leader within the pharmaceutica
RESEARCH TRIANGLE PARK, N.C., Sept. 14, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. today announced that Dr. Bill Sheridan will become chief development officer and will focus on advancing the company's significant pipeline of development candidates. Dr. Ryan Arnold has been appointed as the company's new chief medical officer. Dr. Arnold joins Dr. Sheridan and Dr. Helen Thackray, the company's chief research and development officer, as physicians on the company's leadership team. "Our research and development platform continues to generate exciting opportunities across multiple rare disease targets and Bill's deep knowledge of our portfolio and dedicated focus on our pipelin
RESEARCH TRIANGLE PARK, N.C., March 06, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the compensation committee of BioCryst's board of directors granted seven newly-hired employees restricted stock units (RSUs) covering an aggregate of 65,900 shares of BioCryst common stock. The RSUs were granted as of March 3, 2025, as inducements material to each employee entering into employment with BioCryst. The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs vest in four equal annual installments beginning on the one-year anniversary of the grant date, in each case subject to the new employee's continued service with the com
—ORLADEYO net revenue of $124.2 million for Q4 2024 (+36.6 percent y-o-y) and $437.7 million for FY 2024 (+34.3 percent y-o-y)— —FY 2025 ORLADEYO net revenue guidance increased to between $535-$550 million (previously $515-$535 million)— —GAAP operating loss for full year 2024 was $2.5 million; company achieved $62.9 million non-GAAP operating profit in full year 2024 (not including stock-based compensation), expects to approach positive EPS and positive cash flow in 2H 2025— —Initial clinical data from BCX17725 in Netherton syndrome and avoralstat in diabetic macular edema targeted by end of year— —Company expects to expand ORLADEYO label to children with HAE aged 2 to 11 using oral gra
–Additional real-world studies with ORLADEYO show statistically significant HAE attack rate reductions experienced by patients with C1-INH deficiency and normal C1-INH levels and function– –Data will be presented in five posters at the 2025 American Academy of Allergy, Asthma & Immunology (AAAAI) / World Allergy Organization (WAO) Joint Congress– RESEARCH TRIANGLE PARK, N.C., Feb. 24, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced positive results from an interim analysis of the ongoing APeX-P clinical trial evaluating an oral granule formulation of once-daily ORLADEYO® (berotralstat) in pediatric patients with hereditary angioedema (HAE) aged 2 to
SC 13G/A - BIOCRYST PHARMACEUTICALS INC (0000882796) (Subject)
SC 13G/A - BIOCRYST PHARMACEUTICALS INC (0000882796) (Subject)
SC 13G/A - BIOCRYST PHARMACEUTICALS INC (0000882796) (Subject)
—ORLADEYO net revenue of $124.2 million for Q4 2024 (+36.6 percent y-o-y) and $437.7 million for FY 2024 (+34.3 percent y-o-y)— —FY 2025 ORLADEYO net revenue guidance increased to between $535-$550 million (previously $515-$535 million)— —GAAP operating loss for full year 2024 was $2.5 million; company achieved $62.9 million non-GAAP operating profit in full year 2024 (not including stock-based compensation), expects to approach positive EPS and positive cash flow in 2H 2025— —Initial clinical data from BCX17725 in Netherton syndrome and avoralstat in diabetic macular edema targeted by end of year— —Company expects to expand ORLADEYO label to children with HAE aged 2 to 11 using oral gra
RESEARCH TRIANGLE PARK, N.C., Feb. 10, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its fourth quarter 2024 financial results on Monday, February 24, 2025. BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing 1-844-481-2942 for domestic callers and 1-412-317-1866 for international callers. A live webcast and replay of the call will be available online in the investors section of the company website at www.biocryst.com. About BioCryst Pharmaceuticals BioCryst Pharmaceuticals is a gl
— Q3 2024 ORLADEYO net revenue of $116.3 million (+35.7 percent y-o-y) — — Full-year 2024 ORLADEYO revenue guidance adjusted to $430-$435 million (top end of prior guidance range) — — Company introduces full-year 2024 total product revenue guidance of $443-$448 million based on additional 2024 revenue from RAPIVAB — — BCX17725 for Netherton syndrome advances into the clinic — — Company generates GAAP operating profit of $7.7 million in third quarter ($24.9 million non-GAAP operating profit) — RESEARCH TRIANGLE PARK, N.C., Nov. 04, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today reported financial results for the third quarter ended September 30, 2024, and p
8-K - BIOCRYST PHARMACEUTICALS INC (0000882796) (Filer)
8-K - BIOCRYST PHARMACEUTICALS INC (0000882796) (Filer)
10-K - BIOCRYST PHARMACEUTICALS INC (0000882796) (Filer)
4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)
4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)
4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)
Wedbush initiated coverage of BioCryst Pharma with a rating of Outperform and set a new price target of $15.00
JP Morgan resumed coverage of BioCryst Pharma with a rating of Overweight and set a new price target of $10.00
RBC Capital Mkts upgraded BioCryst Pharma from Sector Perform to Outperform and set a new price target of $10.00 from $9.00 previously